Some interesting stuff from BioHedge over there.
Post# of 72440
"My birds have been telling me of significant meetings happening (or have happened) between leo and C level execs at a company I'd love to have Cellceutix sell to. The catalyst was a deep interest in Kevetrin's progress and results."
Who wouldn't want a p53-activating drug with a strong safety profile?